Versant Ventures
Versant Ventures is a venture capital firm focused on creating and financing biotechnology companies. The firm operates in-house Discovery Engines—multidisciplinary scientific teams with laboratory facilities—that partner with academic founders to launch novel biotech companies. Versant reports global operations, multiple offices and discovery sites, and active participation in company formation, financings, collaborations and exits.
Versant Ventures
Services
Discovery Engines / In-house company creation
Operates multidisciplinary scientific teams and laboratory facilities (Discovery Engines) to identify academic discoveries and form new biotechnology companies. Activities include translational research, initial company formation and early-stage R&D support.
Direct company formation and seed/series financing
Provides capital and structural support to launch and fund early-stage biotechnology companies (examples in content include Series A/B/C financings and firm-led launches).
Partnerships and facilitation of strategic collaborations
Structures and supports collaborations between portfolio companies and large pharmaceutical or biotech partners (examples include collaborations and license agreements cited in press releases).
Discovery Engines / In-house company creation
Operates multidisciplinary scientific teams and laboratory facilities (Discovery Engines) to identify academic discoveries and form new biotechnology companies. Activities include translational research, initial company formation and early-stage R&D support.
Direct company formation and seed/series financing
Provides capital and structural support to launch and fund early-stage biotechnology companies (examples in content include Series A/B/C financings and firm-led launches).
Partnerships and facilitation of strategic collaborations
Structures and supports collaborations between portfolio companies and large pharmaceutical or biotech partners (examples include collaborations and license agreements cited in press releases).
Portfolio
Closed $85M Series B (Jan 9, 2019); Versant announced a successful IPO for Black Diamond (Jan 29, 2020).
#Biotechnology / Targeted oncology
Closed $85M Series B (Jan 9, 2019); Versant announced a successful IPO for Black Diamond (Jan 29, 2020).
#Biotechnology / Targeted oncology